Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …

Abstract The Practice Guidelines Committee of the American Society for Transplantation and
Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to …

Letermovir is approved by the Food and Drug Administration for cytomegalovirus (CMV)
prophylaxis in CMV seropositive recipients of allogeneic stem cell transplantation (alloSCT) …

Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after
allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who …

Abstract Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated
donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant …

Letermovir is the first approved drug for cytomegalovirus (CMV) infection prophylaxis in adult
patients who are CMV positive undergoing allogeneic hematopoietic cell transplantation …

Post-transplantation cyclophosphamide (PTCy) is being increasingly used for graft-versus-
host disease (GVHD) prophylaxis after allogeneic hematopoietic cell transplantation (allo …

Preventing viral infections at an early stage is a key strategy for successfully improving
transplant outcomes. Preemptive therapy and prophylaxis with antiviral agents have been …

Abstract Human herpesvirus 6 (HHV-6) can reactivate after allogeneic hematopoietic stem
cell transplant (allo-HSCT) and may lead to severe symptoms. HHV-6–specific immune …